Generally speaking, experimental drug trials are run first on healthy groups and then in at-risk groups (old, young, those with co-morbidities). From the article, my guess is that they are expediting the sensitive groups trials, but unfortunately there's a lack of technical detail.
Source: My partner is an infectious disease specialist and we talk about this pretty much daily because I'm so curious.